

Genex Pharmaceutical, Inc.  
Form NT 10-Q  
November 14, 2005

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

Commission File Number 002-98997-NY

(Check One):  Form 10-K  Form 20-F  Form 11-K  Form 10-QSB  Form N-SAR  Form N-CSR

For Period Ended: **September 30, 2005**

- Transition Report on Form 10-K
  - Transition Report on Form 20-F
  - Transition Report on Form 11-K
  - Transition Report on Form 10-Q
  - Transition Report on Form N-SAR
- For the Transition Period Ended: \_\_\_\_\_

Read attached instruction sheet before preparing form. Please print or type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

\_\_\_\_\_

PART I -- REGISTRANT INFORMATION

GENEX PHARMACEUTICAL, INC.

-----  
Full name of registrant:

N/A

-----  
Former name if applicable:

1801 Guangyin Building, Youyibeilu, Hexi District

-----  
Address of principal executive office (Street and number):

Tianjin City, China 300074

-----  
City, state and zip code

---

Edgar Filing: Genex Pharmaceutical, Inc. - Form NT 10-Q

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-QSB, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The Company has experienced a delay in completing the information necessary for inclusion in its September 30, 2005 Form 10-QSB Quarterly Report because the Company requires extra time to complete the financial statements for the current quarter. The Company expects to file the Form 10-QSB within the allowed extension period.

PART IV -- OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

|            |             |                    |
|------------|-------------|--------------------|
| Fuzhi Song | (86)        | 22-2337-0440       |
| (Name)     | (Area Code) | (Telephone Number) |

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).  Yes  No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

---

Edgar Filing: Genex Pharmaceutical, Inc. - Form NT 10-Q

GENEX PHARMACEUTICAL, INC.

-----  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2005

By: s/s Fuzhi Song  
Fuzhi Song  
Chief Executive Officer

---